GSK’s fair value estimate has increased from £18.07 to £18.27, indicating a minor but notable shift in analysts’ outlook for ...

Some four years into Jemperli’s commercial lifespan, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio. | Some four years into ...

GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal ...

UK invites pharma executives to help design a new drug-pricing system following a fresh US–UK agreement that raises NHS costs but protects medicine exports.

The FDA’s docket in December includes decisions for two big biologic franchises: BMS’s Breyanzi and Amgen’s Uplizna.

In late November 2025, AnaptysBio announced it had filed a lawsuit against Tesaro (a GSK subsidiary) in Delaware Chancery Court, alleging breaches of their collaboration agreement for Jemperli, while ...

GSK plc will present new data from its haematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (6 - 9 December), reinforcing its potential to redefine ...

GlaxoSmithKline ( ($GB:GSK) ) has shared an announcement. GSK plc announced the grant of options over Ordinary Shares as part of its Share Save ...

Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's ...

GSK's Tesaro sues AnaptysBio over alleged Jemperli contract breaches, putting royalties, milestones, and future licensing ...

As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...